7-azaindole analogs and methods of treating neurological disorders using the same

1 . A compound of Formula I:

wherein

X is selected from hydrogen, deuterium, optionally substituted C 1 -C 8 alkyl, and optionally substituted C 2 -C 8 alkenyl;

Y is an optionally substituted C 1 -C 8 cyclic alkyl or a C 1 -C 4 alkyl that is substituted with at least one aryl group, at least one halo, at least one heteroaryl group, or at least one C 1 -C 8 cyclic alkyl, or Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , and NR 9 ;

W 1 is selected from O, Se, Se(O), SeO 2 , S, S(O), NR 1 , and SO 2 ;

W 2 is selected from —CD 2 -, -CHD-, —(CD 2 ) 2 -, —CH 2 — and —(CH 2 ) 2 —;

Z 4 is CR 4 ;

Z 5 is CR 5 ;

Z 6 is CR 6 ;

Z 7 is N;

R 2 , R 3 , R 3′ , R 6 and R 7 are each independently selected from hydrogen, deuterium, —N(R 9 ) 2 , —SR 9 , halo, optionally substituted C 1 -C 8 alkyl, —C 1 -C 8 alkoxy, and optionally substituted C 2 -C 8 alkenyl, or Y is absent and R 3 taken together with carbon to which it is attached and the nitrogen atom to which X is attached form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , and NR 9 ;

R 4 and R 5 are each independently selected from hydrogen, deuterium, optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, halo, hydroxyl, —N(R 9 ) 2 , —SR 9 , optionally substituted C 1 -C 8 alkoxy, —OC(O)R 8 , —OC(O)OR 8 , —OP(O)(OR 9 ) 2 , and —OSO 2 R 8 ,

wherein at least one of R 4 or R 5 is not hydrogen;

R 1 is selected from hydrogen, deuterium, optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, —C(O)R 8 , —C(O)OR 8 , —P(O)(OR 9 ) 2 , —C(O)N(R 9 ) 2 , —SOR 8 , and —SO 2 R 8 ;

R 8 is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted aryl;

R 9 is independently selected from hydrogen, deuterium, optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted aryl;

and salts, solvates, hydrates, and prodrugs thereof.

2 . The compound of claim 1 , wherein X is an optionally substituted C 1 -C 8 alkyl that is cyclic.

3 . The compound of claim 2 , wherein Y is an optionally substituted C 1 -C 8 cyclic alkyl or a C 1 -C 4 alkyl that is substituted with at least one aryl group, at least one halo, at least one heteroaryl group, or at least one C 1 -C 8 cyclic alkyl.

4 . The compound of claim 3 , wherein Y is a C 1 -C 8 cyclic alkyl group optionally substituted with at least one fluoro group.

5 . The compound of claim 4 , wherein Y is selected from cyclopropyl and cyclobutyl.

6 . The compound of claim 3 , wherein Y is methyl substituted with an optionally substituted aryl group.

7 . The compound of claim 6 , wherein Y is methyl substituted with a phenyl group, wherein the phenyl group is optionally substituted with a halo group or a C 1 -C 8 alkoxy group.

8 . The compound of claim 7 , wherein Y is methyl substituted with a phenyl group, wherein the phenyl group is optionally substituted with fluoro group or a methoxy group.

9 . The compound of claim 1 , wherein R 6 is hydrogen.

10 . The compound of claim 9 , wherein R 4 is selected from hydrogen, halo, hydroxyl, optionally substituted C 1 -C 8 alkoxy and —OC(O)R 8 .

11 . The compound of claim 10 , wherein R 4 is hydrogen.

12 . The compound of claim 11 , wherein R 5 is selected from halo, hydroxyl, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkoxy, and —OC(O)R 8 .

13 . The compound of claim 12 , wherein R 5 is halo.

14 . The compound of claim 13 , wherein R 5 is fluoro.

15 . The compound of claim 12 , wherein R 5 is C 1 -C 8 alkoxy substituted with at least one halo.

16 . The compound of claim 1 , wherein Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , and NR 9 .

17 . The compound of claim 1 , wherein Y is absent and R 3 taken together with carbon to which it is attached and the nitrogen atom to which X is attached form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , and NR 9 .

18 . The compound of claim 1 , wherein W 1 is selected from S and O.

19 . The compound of claim 1 , wherein W 1 is NR 1 .

20 . The compound of claim 19 , wherein the compound is selected from:

and salts, solvates, hydrates, and prodrugs thereof.